Published in J Med Chem on September 23, 2004
Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance. BMC Cancer (2013) 0.77
Study of the cytotoxic/toxic potential of the novel anticancer selenodiazoloquinolone on fibroblast cells and 3D skin model. Interdiscip Toxicol (2017) 0.75
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol (2008) 2.31
Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol (2002) 2.23
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J Med Chem (2008) 1.69
A revised nomenclature for the human and rodent alpha-tubulin gene family. Genomics (2007) 1.68
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer (2007) 1.63
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma (2002) 1.61
Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS One (2009) 1.60
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther (2013) 1.60
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 1.58
Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res (2005) 1.51
Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther (2005) 1.50
A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer (2006) 1.44
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma (2013) 1.43
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol (2002) 1.37
Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents (2005) 1.35
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther (2011) 1.33
Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther (2009) 1.32
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer (2010) 1.31
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res (2007) 1.26
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol (2010) 1.25
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res (2002) 1.20
Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells (2002) 1.16
Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta (2007) 1.16
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res (2004) 1.12
Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res (2012) 1.12
mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci (2008) 1.11
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer (2002) 1.11
BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood (2008) 1.10
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer (2005) 1.09
Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol (2006) 1.09
Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma (2004) 1.07
The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer (2009) 1.06
1-Azaaurones derived from the naturally occurring aurones as potential antimalarial drugs. Bioorg Med Chem (2010) 1.05
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res (2008) 1.02
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol (2008) 1.00
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. Exp Cell Res (2006) 1.00
Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol (2003) 1.00
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs (2011) 0.99
In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res (2009) 0.99
Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.98
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther (2005) 0.97
Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev (2002) 0.97
Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer (2008) 0.97
Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol (2009) 0.95
Discovery of benzylidenebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes. J Med Chem (2006) 0.95
Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem (2012) 0.94
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemother Pharmacol (2006) 0.94
Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening. Biochem Pharmacol (2012) 0.94
Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem Biophys Res Commun (2008) 0.92
In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. Biochem Pharmacol (2003) 0.92
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. Cell Cycle (2008) 0.92
Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS One (2012) 0.92
ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer (2008) 0.92
Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res (2011) 0.92
Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies. Leuk Lymphoma (2003) 0.91
Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a new, powerful lead. J Med Chem (2003) 0.90
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). Hematol J (2002) 0.90
Targeted therapies in metastatic melanoma: toward a clinical breakthrough? Anticancer Agents Med Chem (2010) 0.90
Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity. J Med Chem (2012) 0.89
The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haematologica (2005) 0.89
In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood (2003) 0.89
Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leuk Lymphoma (2005) 0.88
Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Oncogene (2004) 0.87
Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood (2010) 0.87
Structural insights into the inhibition of cytosolic 5'-nucleotidase II (cN-II) by ribonucleoside 5'-monophosphate analogues. PLoS Comput Biol (2011) 0.86
Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk Lymphoma (2003) 0.85
Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol (2013) 0.85
Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases. Eur J Gastroenterol Hepatol (2009) 0.85
Transfection of cells in suspension by ultrasound cavitation. J Control Release (2009) 0.85
Occurrence of the synthetic analgesic tramadol in an African medicinal plant. Angew Chem Int Ed Engl (2013) 0.85
Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer (2002) 0.84
Vinorelbine induces beta3-tubulin gene expression through an AP-1 Site. Anticancer Res (2009) 0.84
Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur J Pharm Sci (2009) 0.84
ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice. PLoS One (2009) 0.84
Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res (2008) 0.83
Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer (2008) 0.83
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol (2008) 0.83
Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leuk Lymphoma (2013) 0.83
Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs (2009) 0.83
Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. J Mol Graph Model (2009) 0.82
Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine. Biochem Pharmacol (2003) 0.82
Sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia. Cancer Lett (2006) 0.82
Inhibition of P-glycoprotein-mediated multidrug efflux by aminomethylene and ketomethylene analogs of reversins. Bioorg Med Chem Lett (2006) 0.82
Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase. Bioorg Med Chem Lett (2006) 0.82
Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.82
Pyrimidine nucleoside analogs in cancer treatment. Expert Rev Anticancer Ther (2003) 0.82